Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial | Synapse
January 1, 2020Open Access
Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial
Key Points
Key points are not available for this paper at this time.
Abstract
Efficacy and Mechanism Evaluation Programme, and National Institute for Health Research and Social Care.